Cancer treatment company BioOra secures $4m funding to scale up
The raise comes ahead of a much larger one next year once first results are through from its second patient trial.
BioOra says automation has enabled it to lower the cost of manufacturing.
Pioneering cancer treatment company BioOra has closed a $4 million pre-Series A funding round that will help scale up its team and manufacturing.
BioOra is the only licensed manufacturer in New Zealand of chimeric antigen receptor (Car-T) cell therapeutics, which has effectively treated certain
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
